Junxun Ma

1.2k citations

45 papers · 796 indexed · h-index 18

Impact in

Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Inflammatory Biomarkers in Disease Prognosis
Pulmonary and Respiratory Medicine top 10%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in ⓘ

Oncology 34
- Cancer Immunotherapy and Biomarkers 24
- Lung Cancer Research Studies 8
- Pancreatic and Hepatic Oncology Research 8
- Colorectal Cancer Treatments and Studies 4
- Inflammatory Biomarkers in Disease Prognosis 4
Pulmonary and Respiratory Medicine 20
- Lung Cancer Treatments and Mutations 16

Co-authors: Yi Hu (30 shared papers)Pengfei Cui (17 shared papers)Haitao Tao (18 shared papers)Jinliang Wang (17 shared papers)Zhefeng Liu (8 shared papers)Shixue Chen (11 shared papers)Yuanyu Qian (7 shared papers)Zhaozhen Wu (10 shared papers)
Journals: Journal of Clinical Oncology (4 papers)Cancer Immunology Immunotherapy (3 papers)Frontiers in Oncology (3 papers)Translational Lung Cancer Research (3 papers)Therapeutic Advances in Medical Oncology (3 papers)
Partner nations: China United States Japan

In The Last Decade

Junxun Ma

42 papers receiving 793 citations

Peers

Countries citing papers authored by Junxun Ma

Since Specialization

Citations

This map shows the geographic impact of Junxun Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junxun Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junxun Ma more than expected).

Fields of papers citing papers by Junxun Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junxun Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junxun Ma. The network helps show where Junxun Ma may publish in the future.

Co-authors

The 25 scholars most cited alongside Junxun Ma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Junxun Ma Line = papers co-authored together Junxun Ma links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study Cancer Medicine ·Pengfei Cui, Zhefeng Liu, Guoqiang Wang, Junxun Ma, Yuanyu Qian, Fan Zhang, Chun Han, Yaping Long, Ye Li, Xuan Zheng, Danyang Sun, Jing Zhang, Shangli Cai, Shunchang Jiao, Yi Hu	2018	90
2	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis Frontiers in Oncology ·Shixue Chen, Zhibo Zhang, Xuan Zheng, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Pengfei Cui, Di Huang, Ziwei Huang, Zhaozhen Wu, Yi Hu	2021	83
3	Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion Oncology Reports ·Nan Du, Xiaosong Li, Fang Li, Hui Zhao, Zhongyi Fan, Junxun Ma, Yan Fu, Huanrong Kang	2013	74
4	The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors Clinical Medicine Insights Oncology ·Zhaozhen Wu, Pengfei Cui, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Shixue Chen, Ziwei Huang, Xuan Zheng, Di Huang, Yi Hu	2021	43
5	Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer Cancer Immunology Immunotherapy ·Danyang Sun, Junxun Ma, Jinliang Wang, Chun Han, Yuanyu Qian, Guang‐Ying Chen, Xiaoyan Li, Juan Zhang, Pengfei Cui, Wushuang Du, Zhaozhen Wu, Shixue Chen, Xuan Zheng, Zhichao Yue, Jia Song, Chan Gao, Xiaochen Zhao, Shangli Cai, Yi Hu	2019	39
6	Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade Frontiers in Oncology ·Jin Shang, Han Xiao, Haoran Zha, Haitao Tao, Xiaoyan Li, Fang Yuan, Guang‐Ying Chen, Lijie Wang, Junxun Ma, Yi Hu	2021	34
7	Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors Frontiers in Immunology ·Zhibo Zhang, Yuan Fang, Runzhe Chen, Ye Li, Junxun Ma, Xiang Yan, Lijie Wang, Fan Zhang, Haitao Tao, Dong Guo, Zhiyue Huang, Sujie Zhang, Xiaoyan Li, Xiaoyu Zhi, Xiangwei Ge, Yi Hu, Jinliang Wang	2020	33
8	Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer Medicine ·Junxun Ma, Sheng Yao, Xiaosong Li, Huanrong Kang, Fangfang Yao, Nan Du	2015	32
9	Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer Therapeutic Advances in Medical Oncology ·Pengfei Cui, Di Huang, Zhaozhen Wu, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Ziwei Huang, Shixue Chen, Xuan Zheng, Yi Hu	2020	28
10	Immunotherapy beyond progression in patients with advanced non-small cell lung cancer Translational Lung Cancer Research ·Xiangwei Ge, Zhibo Zhang, Sujie Zhang, Yuan Fang, Fan Zhang, Xiang Yan, Xiao Han, Junxun Ma, Lijie Wang, Haitao Tao, Xiaoyan Li, Xiaoyu Zhi, Zhiyue Huang, Paul Hofman, Arsela Prelaj, Giuseppe Luigi Banna, Luciano Mutti, Yi Hu, Jinliang Wang	2020	27
11	Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer Targeted Oncology ·Di Huang, Fan Zhang, Haitao Tao, Sujie Zhang, Junxun Ma, Jinliang Wang, Zhefeng Liu, Pengfei Cui, Shixue Chen, Ziwei Huang, Zhaozhen Wu, Lei Zhao, Yi Hu	2020	25
12	Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Therapeutic Advances in Medical Oncology ·Zhibo Zhang, Fan Zhang, Yuan Fang, Ye Li, Junxun Ma, Qiuxiang Ou, Zhefeng Liu, Bo Yang, Lijie Wang, Haitao Tao, Sujie Zhang, Xiaoyan Li, Xiaoyu Zhi, Xiangwei Ge, Hua Bao, Xue Wu, Yi Hu, Jinliang Wang	2020	25
13	<p>Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors</p> Journal of Hepatocellular Carcinoma ·Shixue Chen, Ziwei Huang, Wangping Jia, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Lijie Wang, Pengfei Cui, Zhibo Zhang, Di Huang, Zhaozhen Wu, Xuan Zheng, Yi Hu	2020	24
14	Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients Cancer Immunology Immunotherapy ·Junxun Ma, Danyang Sun, Jinliang Wang, Chun Han, Yuanyu Qian, Guang‐Ying Chen, Xiaoyan Li, Juan Zhang, Pengfei Cui, Wushuang Du, Zhaozhen Wu, Shixue Chen, Xuan Zheng, Zhichao Yue, Jia Song, Chan Gao, Shangli Cai, Yi Hu	2020	23
15	Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer Journal of Chemotherapy ·Yan Fu, Jia Hu, Nan Du, Shunchang Jiao, Li Fang, Xiaosong Li, Junxun Ma, Hui Zhao, Huanrong Kang	2015	21
16	The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel Journal of Cancer ·Wu Zhuang, Junxun Ma, Xudong Chen, Guoqiang Wang, Jing Lü, Yanan Chen, Dong Hua, Shangli Cai, Yuzi Zhang, Xiaochen Zhao, You‐cai Zhu, C. Xu, Yunjian Huang, Zhangzhou Huang, Xiaofeng Zhu, Hong Jiang, Zhijie Wang	2018	20
17	Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors Translational Lung Cancer Research ·Shixue Chen, Ruixin Li, Zhibo Zhang, Ziwei Huang, Pengfei Cui, Wangping Jia, Sujie Zhang, Haitao Tao, Lijie Wang, Xiaoyan Li, Jinliang Wang, Junxun Ma, Zhefeng Liu, Di Huang, Xuan Zheng, Yuichi Saito, Yoshinobu Ichiki, Yi Hu	2021	20
18	Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer Journal of Cancer ·Fan Zhang, Di Huang, Tao Li, Sujie Zhang, Jinliang Wang, Yuzi Zhang, Guoqiang Wang, Zhengyi Zhao, Junxun Ma, Lijie Wang, Danyang Sun, Pengfei Cui, Shangli Cai, Shunchang Jiao, Lei Zhao, Yi Hu	2019	18
19	Expression of HSPA2 in human hepatocellular carcinoma and its clinical significance Tumor Biology ·Yan Fu, Hui Zhao, Xiaosong Li, Huanrong Kang, Junxun Ma, Yao Fang-fang, Nan Du	2014	17
20	Comprehensive analysis of age‐related somatic mutation profiles in Chinese young lung adenocarcinoma patients Cancer Medicine ·Bo Yang, Jie Li, Fang Li, Hongxia Zhou, Weiwei Shi, Huaiyin Shi, Shengjie Sun, Wending Sun, Jinliang Wang, Junxun Ma, Xiang Yan, Yi Hu, Shunchang Jiao	2019	15

About Junxun Ma

Junxun Ma is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Endocrinology, Diabetes and Metabolism and Neurology, having authored 45 papers that have together received 796 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (24 papers), Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (8 papers), Pancreatic and Hepatic Oncology Research (8 papers), Colorectal Cancer Treatments and Studies (4 papers), Inflammatory Biomarkers in Disease Prognosis (4 papers), Hyperglycemia and glycemic control in critically ill and hospitalized patients (4 papers) and Cancer Genomics and Diagnostics (4 papers). The work is most often cited by research in Oncology (596 citations), Pulmonary and Respiratory Medicine (373 citations), Immunology (135 citations), Cancer Research (82 citations) and Hepatology (21 citations). Junxun Ma has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Yi Hu, Pengfei Cui, Haitao Tao, Jinliang Wang, Zhefeng Liu, Shixue Chen, Yuanyu Qian, Zhaozhen Wu, Di Huang and Ziwei Huang. Their work appears in journals such as Journal of Clinical Oncology, Cancer Immunology Immunotherapy, Frontiers in Oncology, Translational Lung Cancer Research and Therapeutic Advances in Medical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact